Despite extensive research and improvements in understanding colorectal cancer (CRC), its
metastatic form continues to pose a substantial challenge, primarily owing to limited …

Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …

The BEACON CRC study demonstrated that encorafenib (Enco)+ cetuximab
(Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux+ …

DNA methyltransferase inhibitor (DNMTi) efficacy in solid tumors is limited. Colon cancer
cells exposed to DNMTi accumulate lysine-27 trimethylation on histone H3 (H3K27me3). We …

Colorectal cancer (CRC) is the third most common malignancy worldwide. It is projected to
increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is …

Simple Summary Immunotherapy has reshaped the prognosis of several tumor types. In
metastatic colorectal cancer, only tumors with microsatellite instability or mismatch repair …

Background We evaluated first-line treatment of metastatic microsatellite-stable colorectal
cancer with short-course oxaliplatin-based chemotherapy alternating with immune …

Despite the approval of immune checkpoint blockade (ICB) therapy for various tumor types,
its effectiveness is limited to only approximately 15% of patients with microsatellite instability …

Colorectal cancer (CRC) is a complex disease with diverse etiologies and clinical outcomes.
Despite considerable progress in development of CRC therapeutics, challenges remain …

Cancer immunotherapy is a rapidly develo** field of medicine that aims to use the host's
immune mechanisms to inhibit and eliminate cancer cells. Antibodies targeting CTLA-4, PD …